✦ LIBER ✦

Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study

✍ Scribed by Lukas A. Hefler; Christoph Grimm; Michael van Trotsenburg; Friedrich Nagele

Book ID: 118445581
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 82 KB
Volume: 84
Category: Article
ISSN: 1556-5653
DOI: 10.1016/j.fertnstert.2005.04.059

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of the aromatase inhibitor anastr

Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study

✍ L. G. Brito; F. J. Candido-dos-Reis; F. A. Magario; M. M. Sabino-de-Freitas 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB

A study of the effects of the aromatase

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer

✍ Fiona M. McCaig; Lorna Renshaw; Linda Williams; Oliver Young; Juliette Murray; E 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 286 KB

A phase II study of a potent and selecti

A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer

✍ H. Koyama 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Reducing the risk of recurrence in postm

Reducing the risk of recurrence in postmenopausal women with early breast cancer: a role for aromatase inhibitors

✍ Nicholas J. Robert 📂 Article 📅 2006 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 154 KB

A Phase III trial comparing anastrozole

A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

✍ Aman U. Buzdar; Stephen E. Jones; Charles L. Vogel; Janet Wolter; Paul Plourde; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

The trial was randomized, double blind for anastrozole, open label for for the Arimidex Study Group megestrol acetate, parallel group, and multicenter. Patients were randomly assigned to receive anastrozole, 1 mg (n Å 128); anastrozole, 10 mg (n Å 130); or

3. A randomized trial of the new specifi

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

✍ W. Jonat; A. Howell; C.P. Blomqvist; W. Eiermann; G. Winblad; C.J. Tyrrell; L. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 435 KB